Surpassing Expectations: Increasing Deal Value Through Better Drug Value Propositions
By failing to properly develop and articulate a strong, payor-oriented value proposition for their drug candidates, biopharmaceutical companies are shortchanging themselves and stunting the value of their assets, and as a result missing out on more lucrative partnering deals.
You may also be interested in...
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.
Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.